Why Is MODERNA INC (MRNA) Stock Moving Today?

Moderna shares fell 17.57% to $202.63, marking the company's worst week in three months. The primary driver was a leak of Phase 3 cancer vaccine data that failed to meet elevated Wall Street expectations, despite showing a 42% reduction in melanoma recurrence or death risk.

What Happened

The stock decline followed the premature release of trial results for Intismeran Autogene, a personalized mRNA cancer therapy developed with Merck. The data indicated that the combination of Intismeran and Keytruda cut the risk of melanoma recurrence or death by 42%. While the results were positive, analysts noted that the figures did not exceed the lofty expectations set by the market. Mizuho analyst Jared Holz stated that the drop reflected a high bar rather than bad data, describing the stock as a do-not-trade due to wild swings. The company is scheduled to present the full data at a conference on Saturday.

What The Data Shows

Moderna has a market capitalization of $96.6 billion and remains unprofitable, with a trailing twelve-month EPS of -8.01 and revenue down 27.6%. The stock's beta is 1.09, and it trades within a 52-week range of $22.28 to $254.48. On October 22, 2026, the stock printed one fresh 52-week high and 48 fresh 52-week lows. Unusual options activity over the last 36 hours included 75 notable prints, with put premium of $120.0 million exceeding call premium of $81.7 million. The largest single print was $22.4 million. Insider filings show five sells totaling $62.6 million in the last 90 days, with no buys. Recent sales include shares by President Stephen Hoge and CFO James M. Mock.

What To Watch

Investors will monitor the official presentation of the Phase 3 melanoma trial data scheduled for Saturday. The stock has moved 6.3% lower over the last eight sessions, falling from $216.25 to $202.63. Coverage breadth remains high, with 50 stories from 24 sources in the last 36 hours.

Why is MRNA stock moving today?

MODERNA INC (MRNA) is drawing unusual attention today. Our newswire has captured 24 stories on MRNA across 13 sources in the last 36 hours, with AI sentiment reading mixed (avg 46/100). The most recent driver: "Moderna, Inc. (MRNA) Presents at 2026 European Society for Medical Oncology (ESMO) Annual Congress - Slideshow" (Seeking Alpha).

Is MRNA a buy right now?

Top Tier Newswire does not give financial advice. Our AI sentiment across the last 36 hours of MRNA coverage reads 46/100 over 24 stories; treat it as a research signal and do your own diligence.

How fast does this page update?

The data sections refresh continuously as the newswire lands coverage; the written analysis is published once per trading day. Pro subscribers additionally get real-time push alerts, watchlists, and the full live terminal.